These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23357134)

  • 1. Nicotinic acid as a lipid-modifying drug--a review.
    Julius U; Fischer S
    Atheroscler Suppl; 2013 Jan; 14(1):7-13. PubMed ID: 23357134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel.
    Shepherd J; Betteridge J; Van Gaal L;
    Curr Med Res Opin; 2005 May; 21(5):665-82. PubMed ID: 15969866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia.
    Parhofer KG
    Vasc Health Risk Manag; 2009; 5():901-8. PubMed ID: 20016845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Multimodal therapy of dyslipidemia].
    Stahn A; Hanefeld M
    Clin Res Cardiol Suppl; 2011 May; 6():10-6. PubMed ID: 22528173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
    Ahmed MH
    J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction of low HDL cholesterol to reduce cardiovascular risk: practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan).
    Vogt A; Kassner U; Hostalek U; Steinhagen-Thiessen E
    Int J Clin Pract; 2007 Nov; 61(11):1914-21. PubMed ID: 17935550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Niacin--an additive therapeutic approach for optimizing lipid profile].
    Wieneke H; Schmermund A; Erbel R
    Med Klin (Munich); 2005 Apr; 100(4):186-92. PubMed ID: 15834527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic role of niacin in dyslipidemia management.
    Boden WE; Sidhu MS; Toth PP
    J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
    Fazio S; Guyton JR; Polis AB; Adewale AJ; Tomassini JE; Ryan NW; Tershakovec AM
    Am J Cardiol; 2010 Feb; 105(4):487-94. PubMed ID: 20152243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Safety and effectiveness of nicotinic acid in the management of patients with chronic renal disease and hyperlipidemia associated to hyperphosphatemia].
    Restrepo Valencia CA; Cruz J
    Nefrologia; 2008; 28(1):61-6. PubMed ID: 18336133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What restricts the clinical use of nicotinic acid?
    Kei A; Liberopoulos EN; Elisaf MS
    Curr Vasc Pharmacol; 2011 Jul; 9(4):521-30. PubMed ID: 21314634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.
    Kim SH; Kim MK; Lee HY; Kang HJ; Kim YJ; Park BJ; Kim HS
    Clin Ther; 2011 Oct; 33(10):1357-64. PubMed ID: 21955937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nicotinic acid in the treatment of hyperlipidaemia.
    Drexel H
    Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():5-6. PubMed ID: 18001312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Niacin for dyslipidemia: considerations in product selection.
    McKenney J
    Am J Health Syst Pharm; 2003 May; 60(10):995-1005. PubMed ID: 12789870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Niacin: chemical forms, bioavailability, and health effects.
    MacKay D; Hathcock J; Guarneri E
    Nutr Rev; 2012 Jun; 70(6):357-66. PubMed ID: 22646128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case for immediate-release niacin.
    Bassan M
    Heart Lung; 2012; 41(1):95-8. PubMed ID: 21414665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins?
    Goumas GS
    Angiology; 2009; 60(1):93-8. PubMed ID: 19019838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place?
    Zeman M; Vecka M; Perlík F; Hromádka R; Staňková B; Tvrzická E; Žák A
    Med Sci Monit; 2015 Jul; 21():2156-62. PubMed ID: 26210594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.